"2>Alcohol and Pregnancy: Why Take the Risk?
April is Alcohol Awareness Month. How much do you know about alcohol use during pregnancy?
Fetal alcohol spectrum disorders (FASDs) are a group of conditions that can occur in a "...
HEMABATE (carboprost tromethamine) Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion:
- Failure of expulsion of the fetus during the course of treatment by another method;
- Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity;
- Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus;
- Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.
HEMABATE (carboprost tromethamine) is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of HEMABATE (carboprost tromethamine) has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, HEMABATE (carboprost tromethamine) used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention.
DOSAGE AND ADMINISTRATION
Abortion and Indications 1-4
An initial dose of 1 mL of HEMABATE (carboprost tromethamine) Sterile Solution (containing the equivalent
of 250 micrograms of carboprost) is to be administered deep in the muscle with
a tuberculin syringe. Subsequent doses of 250 micrograms should be administered
at 1½ to 3½ hour intervals depending on uterine response.
An optional test dose of 100 micrograms (0.4 mL) may be administered initially. The dose may be increased to 500 micrograms (2 mL) if uterine contractility is judged to be inadequate after several doses of 250 micrograms (1 mL).
The total dose administered of carboprost tromethamine should not exceed 12 milligrams and continuous administration of the drug for more than two days is not recommended.
For Refractory Postpartum Uterine Bleeding
An initial dose of 250 micrograms of HEMABATE (carboprost tromethamine) Sterile Solution (1 mL of HEMABATE (carboprost tromethamine) ) is to be given deep, intramuscularly. In clinical trials it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events. The total dose of HEMABATE (carboprost tromethamine) should not exceed 2 milligrams (8 doses).
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
HEMABATE (carboprost tromethamine) Sterile Solution is available in the following packages:
1 mL ampoules NDC 0009-0856-05
10 x 1 mL ampoules NDC 0009-0856-08
Each mL of HEMABATE contains carboprost tromethamine equivalent to 250 mcg of carboprost.
HEMABATE (carboprost tromethamine) must be refrigerated at 2° to 8° C (36° to 46° F).
Revised March 2006. Distributed by: Pharmacia & Upjohn Co., Division of Pfizer Inc, NY, NY 10017. FDA rev date: 10/15/2002
Last reviewed on RxList: 5/7/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Hemabate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Parenting and Pregnancy
Get tips for baby and you.